… avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication
that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On …

… We conducted a systematic review until 1 November 2022 searching for randomized
controlled trials (RCTs) involving COVID-19 patients comparing molnupiravir [±standard of care (…

… Molnupiravir initially emerged as a possible treatment of influenza viruses, encephalitic
alphaviruses like Venezuelan, Eastern and Western equine encephalitic viruses due to its …

… systematic review and meta-analysis provides a comprehensive overview of the evidence for
molnupiravir in treating … Molnupiravir treatment for patients with mild or moderate COVID-19 …

… The included studies in this systematic review were (N = 60) included 39 published papers
and 21 clinical trials. After Manual addition (N = 4), the qualitative assessment included (N = …

… There are currently some differences in the research results of molnupiravir. This study
aimed to evaluate the efficacy and safety of molnupiravir in the treatment of COVID-19. …

… This systematic review represents the most comprehensive summary thus far of … molnupiravir
in treating patients with mild-to-moderate COVID-19. Our findings reveal that molnupiravir …

… Authorization in three countries for the treatment of mild COVID-19. The aim of this systematic
review was to find out the safety and efficacy of Molnupiravir in SARS-COV-2 infections. …

… systematic review and network meta-analysis addressing the comparative effectiveness of
antiviral drugs for nonsevere COVID-19, we found that molnupiravir and … than molnupiravir at …

… determine which oral antiviral treatment (nirmatrelvir/ritonavir or molnupiravir) is more effective
… of nirmatrelvir/ritonavir compared with molnupiravir in the treatment of COVID-19 patients. …